|
1
|
Jemal A, Bray F, Center MM, et al: Global
cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Center MM, Jemal A, Lortet-Tieulent J, et
al: International variation in prostate cancer incidence and
mortality rates. Eur Urol. 61:1079. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Utomo NB, Mochtar CA and Umbas R: Primary
hormonal treatment in localized and locally advanced prostate
cancer: effectiveness and survival predictive factors. Acta Med
Indones. 44:10–15. 2012.PubMed/NCBI
|
|
5
|
Ferlay J, Parkin DM and Steliarova-Foucher
E: Estimates of cancer incidence and mortality in Europe in 2008.
Eur J Cancer. 46:765–781. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Molitierno J, Evans A, Mohler JL, et al:
Characterization of biochemical recurrence after radical
prostatectomy. Urol Int. 77:130–134. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stephenson AJ, Scardino PT, Eastham JA, et
al: Postoperative nomogram predicting the 10-year probability of
prostate cancer recurrence after radical prostatectomy. J Clin
Oncol. 23:7005–7012. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shariat SF, Karakiewicz PI, Roehrborn CG
and Kattan MW: An updated catalog of prostate cancer predictive
tools. Cancer. 113:3075–3099. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alers JC, Rochat J, Krijtenburg PJ, Hop
WC, Kranse R, Rosenberg C, Tanke HJ, Schröder FH and van Dekken H:
Identification of genetic markers for prostatic cancer progression.
Lab Invest. 80:931–942. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cuzick J, Swanson GP, Fisher G, et al:
Prognostic value of an RNA expression signature derived from cell
cycle proliferation genes in patients with prostate cancer: a
retrospective study. Lancet Oncol. 12:245–255. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Arsov C, Jankowiak F, Hiester A, Rabenalt
R, Quentin M, Schimmller L, Blondin D, Antoch G and Albers P:
Prognostic value of a cell-cycle progression score in men with
prostate cancer managed with active surveillance after MRI-guided
prostate biopsy - a pilot study. Anticancer Res. 34:2459–2466.
2014.PubMed/NCBI
|
|
12
|
Cooperberg MR, Simko JP, Cowan JE, et al:
Validation of a cell-cycle progression gene panel to improve risk
stratification in a contemporary prostatectomy cohort. J Clin
Oncol. 31:1428–1434. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Varis A, Salmela AL and Kallio MJ: Cenp-F
(mitosin) is more than a mitotic marker. Chromosoma. 115:288–295.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liao H, Winkfein RJ, Mack G, Rattner JB
and Yen TJ: CENP-F is a protein of the nuclear matrix that
assembles onto kinetochores at late G2 and is rapidly degraded
after mitosis. J Cell Biol. 130:507–518. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rattner JB, Rao A, Fritzler MJ, Valencia
DW and Yen TJ: CENP-F is a ca 400 kDa kinetochore protein that
exhibits a cell-cycle dependent localization. Cell Motil
Cytoskeleton. 26:214–226. 1993. View Article : Google Scholar
|
|
16
|
Hussein D and Taylor SS: Farnesylation of
Cenp-F is required for G2/M progression and degradation after
mitosis. J Cell Sci. 115:3403–3414. 2002.PubMed/NCBI
|
|
17
|
Brendle A, Brandt A, Johansson R, Enquist
K, Hallmans G, Hemminki K, Lenner P and Forsti A: Single nucleotide
polymorphisms in chromosomal instability genes and risk and
clinical outcome of breast cancer: a Swedish prospective
case-control study. Eur J Cancer. 45:435–442. 2009. View Article : Google Scholar
|
|
18
|
Dai Y, Liu L, Zeng T, Zhu YH, Li J, Chen
L, Li Y, Yuan YF, Ma S and Guan XY: Characterization of the
oncogenic function of centromere protein F in hepatocellular
carcinoma. Biochem Biophys Res Commun. 436:711–718. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen WB, Cheng XB, Ding W, Wang YJ, Chen
D, Wang JH and Fei RS: Centromere protein F and survivin are
associated with high risk and a poor prognosis in colorectal
gastrointestinal stromal tumours. J Clin Pathol. 64:751–755. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cao JY, Liu L, Chen SP, et al: Prognostic
significance and therapeutic implications of centromere protein F
expression in human nasopharyngeal carcinoma. Mol Cancer.
9:2372010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Erlanson M, Casiano CA, Tan EM, Lindh J,
Roos G and Landberg G: Immunohistochemical analysis of the
proliferation associated nuclear antigen CENP-F in non-Hodgkin’s
lymphoma. Mod Pathol. 12:69–74. 1999.PubMed/NCBI
|
|
22
|
Shigeishi H, Mizuta K, Higashikawa K,
Yoneda S, Ono S and Kamata N: Correlation of CENP-F gene expression
with tumor-proliferating activity in human salivary gland tumors.
Oral Oncol. 41:716–722. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Albino D, Scaruffi P, Moretti S, Coco S,
Truini M, Di Cristofano C, Cavazzana A, Stigliani S, Bonassi S and
Tonini GP: Identification of low intratumoral gene expression
heterogeneity in neuroblastic tumors by genome-wide expression
analysis and game theory. Cancer. 113:1412–1422. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Taylor BS, Schultz N, Hieronymus H, et al:
Integrative genomic profiling of human prostate cancer. Cancer
Cell. 18:11–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
O’Brien SL, Fagan A, Fox EJ, et al: CENP-F
expression is associated with poor prognosis and chromosomal
instability in patients with primary breast cancer. Int J Cancer.
120:1434–1443. 2007. View Article : Google Scholar
|
|
26
|
Kim HE, Kim DG, Lee KJ, et al: Frequent
amplification of CENPF, GMNN and CDK13 genes in hepatocellular
carcinomas. PLoS One. 7:e432232012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Aytes A, Mitrofanova A, Lefebvre C, et al:
Cross-species regulatory network analysis identifies a synergistic
interaction between FOXM1 and CENPF that drives prostate cancer
malignancy. Cancer Cell. 25:638–651. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mi YJ, Gao J, Xie JD, et al: Prognostic
relevance and therapeutic implications of centromere protein F
expression in patients with esophageal squamous cell carcinoma. Dis
Esophagus. 26:636–643. 2013. View Article : Google Scholar
|
|
29
|
Bomont P, Maddox P, Shah JV, Desai AB and
Cleveland DW: Unstable microtubule capture at kinetochores depleted
of the centromere-associated protein CENP-F. EMBO J. 24:3927–3939.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Feng J, Huang H and Yen TJ: CENP-F is a
novel microtubule-binding protein that is essential for kinetochore
attachments and affects the duration of the mitotic checkpoint
delay. Chromosoma. 115:320–329. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Holt SV, Vergnolle MA, Hussein D, Wozniak
MJ, Allan VJ and Taylor SS: Silencing Cenp-F weakens centromeric
cohesion, prevents chromosome alignment and activates the spindle
checkpoint. J Cell Sci. 118:4889–4900. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ma L, Zhao X and Zhu X: Mitosin/CENP-F in
mitosis, transcriptional control, and differentiation. J Biomed
Sci. 13:205–213. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jefford CE and Irminger-Finger I:
Mechanisms of chromosome instability in cancers. Crit Rev Oncol
Hematol. 59:1–14. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dancik GM and Theodorescu D: Robust
prognostic gene expression signatures in bladder cancer and lung
adenocarcinoma depend on cell cycle related genes. PLoS One.
9:e852492014. View Article : Google Scholar : PubMed/NCBI
|
